Free Cash Flow per Share: A measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. Calculated as: Free Cash Flow / Weighted Average Shares Outstanding (Diluted)
Spyre Therapeutics, Inc. (SYRE) had Free Cash Flow per Share of $-1.50 for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-36.20M |
|
-- |
|
-- |
|
$41.64M |
|
$-41.64M |
|
$5.44M |
|
$-36.20M |
|
$-36.20M |
|
$-36.20M |
|
$-36.20M |
|
$-36.20M |
|
$-36.20M |
|
$-41.64M |
|
$-41.64M |
|
84.73M |
|
84.73M |
|
$-0.36 |
|
$-0.36 |
|
| Balance Sheet Financials | |
$1.17B |
|
-- |
|
-- |
|
$1.17B |
|
$63.30M |
|
-- |
|
$8.56M |
|
$71.86M |
|
$954.72M |
|
$1.10B |
|
$1.10B |
|
88.06M |
|
| Cash Flow Statement Financials | |
$-127.25M |
|
$-241.32M |
|
$444.86M |
|
$85.72M |
|
$162.01M |
|
$76.29M |
|
$26.32M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
18.53 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-127.25M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-3.79% |
|
-3.29% |
|
-3.09% |
|
-3.29% |
|
$12.50 |
|
|
Free Cash Flow per Share |
$-1.50 |
$-1.50 |
|